What syndrome is indicated by a mutation in the STK11 (serine/threonine kinase 11) gene?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 31, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

STK11 mutation is associated with Peutz-Jeghers syndrome (PJS), a rare autosomal dominant genetic disorder characterized by the development of hamartomatous polyps in the gastrointestinal tract and distinctive mucocutaneous pigmentation. The STK11 gene, also known as LKB1, is a tumor suppressor gene that encodes a serine/threonine kinase involved in cell polarity and energy metabolism regulation 1. When mutated, it disrupts normal cellular functions, leading to polyp formation and increased cancer susceptibility. Patients with PJS have an increased risk of developing various cancers, including gastrointestinal, breast, ovarian, and pancreatic cancers. Key features of PJS include:

  • Hamartomatous polyps in the gastrointestinal tract
  • Mucocutaneous melanin pigmentation
  • Increased risk of gastrointestinal and nongastrointestinal tumors
  • Autosomal dominant inheritance pattern Management of PJS involves regular surveillance with endoscopic procedures starting in childhood or adolescence, breast cancer screening, and monitoring for other associated malignancies, as recommended by the NCCN guidelines 1. Genetic counseling is also recommended for affected individuals and their families to understand inheritance patterns and cancer risks. The most recent guidelines from the NCCN recommend referral to a specialized team and participation in available clinical trials for patients who meet clinical criteria for PJS or have a pathogenic or likely pathogenic variant in STK11 1. Additionally, the guidelines recommend annual pelvic examination and Papanicolaou test starting at around ages 18 to 20 years, as well as annual pelvic ultrasound, to monitor for gynecologic cancer. Overall, the management of PJS requires a multidisciplinary approach, including genetic counseling, surveillance, and screening for associated malignancies, to reduce the risk of morbidity and mortality associated with this condition 1.

From the Research

Syndrome Indicated by STK11 Mutation

The syndrome indicated by STK11 mutation is Peutz-Jeghers syndrome (PJS), a rare autosomal dominant polyposis syndrome characterized by gastrointestinal hamartomatous polyps, mucocutaneous hyperpigmentation, and an increased risk of cancer 2, 3, 4, 5, 6.

Key Characteristics of Peutz-Jeghers Syndrome

  • Gastrointestinal hamartomatous polyps
  • Mucocutaneous hyperpigmentation
  • Increased risk of cancer
  • Autosomal dominant inheritance pattern

STK11 Gene Mutations in Peutz-Jeghers Syndrome

  • Truncating mutations in the STK11 gene are associated with more severe complications, including more polyps, surgical interventions, and cancers 2, 3
  • Non-truncating mutations may also be associated with an increased risk of cancer, although the risk may be lower than with truncating mutations 2
  • Specific mutations in the STK11 gene, such as those affecting protein kinase domain XI, may be associated with a higher risk of dysplastic polyps and cancer 4

Clinical Management of Peutz-Jeghers Syndrome

  • Regular endoscopic surveillance to detect and remove polyps
  • Surgical intervention may be necessary to remove large or symptomatic polyps
  • Close monitoring for signs of cancer and other complications
  • Genetic counseling and testing for family members may be recommended 5, 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.